Cargando…
A203 EARLY PROACTIVE DRUG MONITORING STRATEGY OF INFLIXIMAB AS MONOTHERAPY FOR INFLAMMATORY BOWEL DISEASE IN PAEDIATRIC PATIENTS IS ASSOCIATED WITH GOOD SUSTAINED CLINICAL REMISSION
BACKGROUND: Monotherapy with Infliximab (IFX) can be as efficient as combotherapy with immunomodulators in the treatment and maintenance of remission for children with inflammatory bowel disease (IBD) if an early proactive therapeutic drug monitoring strategy is adequately performed. This strategy m...
Autores principales: | Girard, C, Ackhar, S, Sassine, S, Chapuy, L, Jantchou, P, Deslandres, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991299/ http://dx.doi.org/10.1093/jcag/gwac036.203 |
Ejemplares similares
-
Phenotype and outcomes of very early onset and early onset inflammatory bowel diseases in a Montreal pediatric cohort
por: Chapuy, Laurence, et al.
Publicado: (2023) -
A188 FACTORS ASSOCIATED WITH CLINICAL REMISSION IN PEDIATRIC LUMINAL CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022) -
Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study
por: Sassine, Samuel, et al.
Publicado: (2021) -
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
por: Wilson, Aze, et al.
Publicado: (2021) -
A253 IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON PHYSICAL ACTIVITY LEVELS IN CHILDREN AND ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE IN QUEBEC
por: Bouthot, J, et al.
Publicado: (2022)